Axhidrox 2,2 mg po potisku krema Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

axhidrox 2,2 mg po potisku krema

dr. august wolff gmbh & co. kg arzneimittel, sudbrackstrasse 56, bielefeld, njemačka - glikopironijev bromid - krema - urbroj: 1 g kreme sadrži glikopironijev bromid, što odgovara 8 mg glikopironija jednim potiskom pumpice isporučuje se 270 mg kreme koja sadrži glikopironijev bromid što odgovara 2,2 mg glikopironija

Camzyos Europska Unija - hrvatski - EMA (European Medicines Agency)

camzyos

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - ostali srčani pripravci - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Victrelis Europska Unija - hrvatski - EMA (European Medicines Agency)

victrelis

merck sharp dohme ltd - Боцепревир - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - victrelis je indiciran za liječenje kroničnog hepatitisa c (chc) genotipa 1 infekcije, u kombinaciji s peginterferonom alfa i ribavirinom u odraslih bolesnika s kompenziranom bolešću jetre koji prethodno nisu bili liječeni ili nisu odgovorili na prethodnu terapiju.

Skyrizi Europska Unija - hrvatski - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresivi - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Idefirix Europska Unija - hrvatski - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresivi - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.